Powered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates genomic, epigenomic and RNA-based molecular data First tissue comprehensive genomic profiling test to offer ...

Please provide your email address to receive an email when new articles are posted on . A lipid profiling blood test may predict the risk for type 2 diabetes and CVD years in advance, according to ...

--Landmark approval advances personalized cancer care as an estimated 1 in 3 patients across five common advanced cancers are expected to match with an FDA-approved therapy-- CAMBRIDGE, ...

Characterization of Non–Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns Among 31,165 (97.2%) samples where ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has received new commercial health plan coverage for the ...

Oncotarget published "Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra®" which reported that the authors developed and analytically validated a ...

The DNA sequencing giant Illumina has launched a new in vitro diagnostic test in Europe designed to profile various cancer mutations and help direct patients to targeted therapies. Built off of its ...

GUARDANT HEALTH LAUNCHES GUARDANT360 TISSUE, FIRST TISSUE MOLECULAR PROFILING TEST WITH COMPREHENSIVE MULTIOMIC ANALYSIS TO PROVIDE A MORE COMPLETE VIEW OF CANCER Powered by Guardant Infinity smart ...